Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Acceleron Pharma (XLRN) Share Price
Media coverage about Acceleron Pharma (NASDAQ:XLRN) has trended somewhat positive on Sunday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Acceleron Pharma earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 44.871564313594 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several brokerages have recently weighed in on XLRN. BidaskClub upgraded Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Cann reiterated a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. Royal Bank of Canada reiterated a “hold” rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. Finally, Barclays upped their price objective on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $44.56.
Acceleron Pharma (XLRN) opened at $45.12 on Friday. Acceleron Pharma has a twelve month low of $23.07 and a twelve month high of $45.52. The company has a market capitalization of $1,986.27, a P/E ratio of -17.42 and a beta of 1.59.
In other Acceleron Pharma news, EVP Matthew L. Sherman sold 4,633 shares of the company’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $42.71, for a total transaction of $197,875.43. Following the transaction, the executive vice president now directly owns 77,700 shares in the company, valued at $3,318,567. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin F. Mclaughlin sold 19,000 shares of the company’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $42.89, for a total value of $814,910.00. Following the transaction, the chief financial officer now owns 45,300 shares in the company, valued at $1,942,917. The disclosure for this sale can be found here. Insiders have sold 135,021 shares of company stock worth $5,034,598 over the last 90 days. 3.90% of the stock is owned by insiders.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Acceleron Pharma (XLRN) Share Price” was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://theolympiareport.com/2018/01/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-acceleron-pharma-xlrn-share-price.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.